Gene Silencing Pharma Companies RNA Vaccine 
pharmaphorum
DECEMBER 23, 2020
It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition. Rare disease progress.
Drug Discovery World
OCTOBER 4, 2022
The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. .
Expert insights. Personalized for you.
80 
Let's personalize your content